Clinical Trial Update: A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase I dose-escalation study evaluating the safety and pharmacokinetics of LAM-002A in patients with Non-Hodgkin lymphoma and chronic lymphocytic leukemia; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• LAM-002A (LAM-002A)

Snippet

Sponsor: OrphAI Therapeutics | Conditions: Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic | Phase 1 | Status: COMPLETED | Results posted: 2024-08-22